| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1989.7.4.425 |
| P698 | PubMed publication ID | 2926468 |
| P2093 | author name string | J D Ahlgren | |
| J G Fryer | |||
| J J Lokich | |||
| J J Gullo | |||
| J A Philips | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic colorectal carcinoma | Q108607277 |
| fluorouracil | Q238512 | ||
| P304 | page(s) | 425-432 | |
| P577 | publication date | 1989-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study | |
| P478 | volume | 7 |
| Q53513591 | 20th-century advances in drug therapy in oncology--Part I. |
| Q74202035 | 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer |
| Q41153872 | 5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? multivariate meta-analysis of the literature |
| Q43051297 | 5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? |
| Q36810361 | 5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical Studies |
| Q34253978 | 5-Fluorouracil derivatives: a patent review. |
| Q40666128 | 5-Fluorouracil-cisplatin adducts with potential antitumor activity. |
| Q33750445 | 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy |
| Q28359288 | 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer |
| Q77949174 | 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules |
| Q34127889 | A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy |
| Q35993743 | A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas |
| Q77533706 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study |
| Q43000487 | A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect. |
| Q44458772 | A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice |
| Q73923794 | A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer |
| Q41963946 | A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma |
| Q36136107 | A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer |
| Q34315576 | A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck |
| Q73893876 | A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer |
| Q36135201 | A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer |
| Q36973778 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer |
| Q44715299 | A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum |
| Q36079784 | A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases |
| Q33489857 | A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer |
| Q51546518 | A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. |
| Q33501101 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer |
| Q43596239 | A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients |
| Q36102819 | A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard) |
| Q48247027 | A rare case of non-immune hemolytic anemia in a patient with metastatic breast cancer treated with capecitabine |
| Q77128596 | A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) |
| Q33783647 | AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association |
| Q54253599 | Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. |
| Q33490610 | Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study |
| Q73308572 | Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer |
| Q38862820 | Advances in oral delivery of anti-cancer prodrugs |
| Q44427270 | Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). |
| Q36024905 | Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. |
| Q41247362 | Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. |
| Q44541306 | Ambulatory chemotherapy |
| Q28346767 | Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer |
| Q44360855 | Apoptosis in normal tissues induced by anti-cancer drugs |
| Q41604531 | Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council |
| Q73155409 | Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) |
| Q35976676 | Bioavailability and feasibility of subcutaneous 5-fluorouracil |
| Q37080091 | Biochemical Basis for Circadian-Dependent Metabolism of Fluoropyrimidines |
| Q77128658 | Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group |
| Q80510550 | Cancers of the large bowel and hepatobiliary tract |
| Q40409795 | Central venous access catheters. |
| Q61868299 | Chemotherapy for advanced pancreatic cancer - some light at the end of the tunnel? |
| Q78478993 | Chemotherapy for colorectal cancer |
| Q40484654 | Chemotherapy in Colorectal Carcinoma |
| Q77203325 | Chemotherapy in advanced pancreatic adenocarcinoma |
| Q73526632 | Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial |
| Q33343214 | Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck |
| Q34084272 | Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors |
| Q42218659 | Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours |
| Q68548263 | Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer |
| Q67543146 | Colorectal cancer |
| Q41579445 | Colorectal cancer--is there an alternative to 5-FU? |
| Q93911723 | Colorectal cancer: treatment of advanced disease |
| Q73093121 | Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer |
| Q70611518 | Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study |
| Q36141244 | Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours |
| Q44181002 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. |
| Q72065579 | Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusion |
| Q71170198 | Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges |
| Q44016718 | Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial |
| Q73206714 | Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group |
| Q35050277 | Complications of hepatic artery infusion: a review of 4580 reported cases |
| Q34084250 | Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan |
| Q36079497 | Continuous 5-fluorouracil in the treatment of breast cancer |
| Q67760115 | Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin |
| Q36081891 | Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma |
| Q40859631 | Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine |
| Q73668731 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer |
| Q35097713 | Curative treatment of gastric cancer: towards a multidisciplinary approach? |
| Q45938898 | Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. |
| Q40423737 | Current chemotherapeutic possibilities in the treatment of colorectal cancer |
| Q44607726 | Cutaneous Hand and Foot Toxicity Associated With Cancer Chemotherapy |
| Q38242295 | Cytotoxic drugs for gastric and colorectal cancer |
| Q38254307 | DNA synthesis inhibitors for the treatment of gastrointestinal cancer |
| Q43578599 | Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival |
| Q40022137 | Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas |
| Q33442997 | Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents |
| Q34427755 | Disease management considerations: disease management considerations |
| Q41419015 | Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents |
| Q36217005 | Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil |
| Q36079721 | Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study |
| Q37104107 | Doxifluridine in advanced colorectal cancer |
| Q36711475 | Drug treatment of colorectal cancer. Current status |
| Q43777233 | E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo |
| Q42768404 | Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals. |
| Q73128670 | Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo |
| Q43230727 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats |
| Q46864342 | Effectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer |
| Q61868327 | Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival |
| Q41712943 | Establishing a programme for continuous ambulatory infusion chemotherapy |
| Q46448482 | FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients |
| Q46750925 | Feasibility of measuring 5-fluorouracil catabolic potential by oral loading |
| Q74646473 | First experience and technical aspects of isolated liver perfusion for extensive liver metastasis |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q74028608 | Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen |
| Q47618482 | Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe |
| Q73258129 | Gastrointestinal cancer in the elderly |
| Q34325090 | Gastrointestinal malignancies |
| Q35584405 | HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome |
| Q72112446 | Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy |
| Q44943214 | High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients |
| Q41148056 | How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer |
| Q77658442 | Immediate postoperative 5-FU does not decrease colonic anastomotic strength |
| Q33859998 | Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines |
| Q36821382 | Infusion pumps for systemic and intra-arterial chemotherapy of colorectal liver metastases. |
| Q41419088 | Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience |
| Q40935423 | Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance |
| Q70655786 | Intermittent continuous intravenous infusion of 5-fluorouracil; a useful approach in disseminated colorectal cancer? |
| Q41160084 | Intra-hepatic arterial drug delivery |
| Q42619097 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. |
| Q86273560 | Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer |
| Q43557094 | Latent hematopoietic stem cell toxicity associated with protracted drug administration |
| Q73481598 | Liver metastases from colorectal cancer |
| Q28273580 | Local treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaT |
| Q42285544 | Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial |
| Q78111183 | Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery |
| Q44458770 | Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1. |
| Q92839397 | Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q34788235 | Management of colorectal cancer. |
| Q77621017 | Management of hepatic metastases from colorectal cancer: systemic chemotherapy |
| Q36291303 | Mature results from three large controlled studies with raltitrexed ('Tomudex'). |
| Q73597514 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand |
| Q52170109 | Mechanisms of Action and Modulation of Fluorouracil. |
| Q41449440 | Mechanistic Model for Cancer Growth and Response to Chemotherapy |
| Q70733006 | Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo |
| Q35148795 | Metastatic colorectal cancer: systemic treatment in the new millennium |
| Q67760095 | Multiple confirmatory trials. How can additional studies be of value? |
| Q45275933 | New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction |
| Q35687709 | New oral drugs in older patients: a review of idarubicin in elderly patients. |
| Q40742190 | Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo |
| Q43634493 | Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma |
| Q28364999 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer |
| Q33362775 | Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study |
| Q33499176 | Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer |
| Q34746001 | Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD |
| Q57693104 | Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration |
| Q44317716 | Palliative treatment for colorectal cancer |
| Q34731381 | Personalized colon cancer care in 2010. |
| Q38166233 | Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. |
| Q34402152 | Perspectives in cancer chemotherapy |
| Q47312464 | Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data |
| Q36079774 | Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma |
| Q44663671 | Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer |
| Q36053398 | Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients |
| Q24810562 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer |
| Q72678287 | Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients |
| Q46527662 | Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies |
| Q33329060 | Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. |
| Q28361226 | Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer |
| Q55389497 | Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02). |
| Q35982309 | Phase II trial of UFT in advanced colorectal and gastric cancer |
| Q33490481 | Phase II trial of intravenous melphalan in advanced colorectal carcinoma |
| Q36604241 | Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01). |
| Q28370847 | Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid |
| Q36671793 | Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil |
| Q39374122 | Preoperative infusional chemoradiation therapy for Stage T3 rectal cancer |
| Q34067396 | Progress in colorectal cancer chemotherapy: how far have we come, how far to go? |
| Q40387127 | Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials |
| Q36136453 | Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. |
| Q37679097 | Protracted intravenous infusion of 5-fluorouracil in combination treatments. A review |
| Q36621976 | Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study |
| Q41724957 | Radiation Therapy With 5-fluorouracil in Head and Neck Cancer |
| Q33862744 | Radiation Therapy and 5-Fluorouracil in Pancreatic Cancer |
| Q43764500 | Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma |
| Q73379732 | Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials |
| Q42645967 | Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies |
| Q33493519 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer |
| Q44723860 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma |
| Q58614979 | Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study |
| Q77632445 | Rational development of capecitabine |
| Q36388048 | Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy |
| Q77621043 | Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole |
| Q52882377 | Response rates--an evolution. |
| Q30431857 | Review article: current treatment and optimal patient management in pancreatic cancer. |
| Q37974935 | S-1 as a core anticancer fluoropyrimidine agent |
| Q40585342 | S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects |
| Q28352371 | Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with [...] |
| Q73355992 | Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers |
| Q36294882 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study |
| Q33332077 | Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study |
| Q33352047 | Selecting dose-intense drug combinations: metastatic breast cancer |
| Q57758641 | Should patients with advanced colorectal cancer be treated with chemotherapy? |
| Q37015697 | Targeted therapies in colorectal cancer: surgical considerations |
| Q33859971 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil |
| Q71971495 | The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat |
| Q34761260 | The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil |
| Q33389163 | The efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data). |
| Q41657916 | The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon |
| Q34211250 | The oral fluorinated pyrimidines |
| Q36101808 | The role of chemotherapy in colon cancer. |
| Q34084253 | The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential |
| Q34501956 | The use of chemoradiotherapy in oesophageal cancer |
| Q55311755 | Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. |
| Q33499869 | Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study |
| Q40900115 | Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy |
| Q37340518 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer |
| Q41352142 | Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits |
| Q93635367 | Upcoming articles |
| Q33367028 | Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity |
| Q37293135 | Vascular complications of selected cancer therapies |
| Q54116133 | Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. |
| Q36136402 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer |
| Q40423816 | ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer |
| Q82296124 | [Principles of the treatment of peritoneal carcinomatosis due to colorectal cancer. Current review and update] |
| Q51035952 | p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. |
| Q55158991 | p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. |
Search more.